Sutent now a first line therapy for RCC in Europe

Wyeth's Torisel granted priority review

The first mTor inhibitor has been granted priority review. Approval is requested for RCC, which puts it in direct competition with Nexavar and Sutent. As Torisel is fast-tracked, performance is likely impressive and perhaps superior. I wonder if Onyx/Bayer or Pfizer is already talking to Wyeth about conducting combination trials.

Pfizer's pipeline

forbes gives the highlights of Pfizer's pipeline, which includes 3 drugs targeting kinases:

Axitinib - Sutent successor, firstly for RCC, with picomolar potency vs.VEGFR 1, 2 & 3 and nanomolar potency against PDGFR-beta and KIT, which, according to Forbes is "moving soon into final stage trials for thyroid breast and lung cancer."

CP-751871 - IGFR-1 Ab for prostate and lung cancer, now in P2.

CP-690550: JAK3 inhibitor for RA

I'll dig into Pfizer's news to see what else they're touting.....